MercadoLibre Inc (MELI34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 74.65 |
|---|---|
| 52-week range | 61.35 – 108.69 |
| Return, 1 month / 3 months | −1.1% / −3.3% |
| Return, 1 year / 3 years | −27.2% / +48.5% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 36.5% |
| Worst drawdown (1 year) | -40.5% |
| Average daily value traded | 110.27M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
MercadoLibre is an Argentine company that runs an online marketplace where people and businesses across Latin America buy and sell goods, alongside logistics services that help sellers ship orders. Its Mercado Pago arm provides digital payments, wallets and related financial services to shoppers and merchants, while its advertising and credit offerings support sellers on the platform. The company is based in Buenos Aires and serves customers throughout the region.
MercadoLibre Inc is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code MELI34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
MercadoLibre Inc (MELI34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 74.65 on 27 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 879 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.2% and over the last three months it fell 3.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.1% | ||
| From 52-week high | -29.9% | ||
| Momentum | 26 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -3.3% | ||
| 6-month return | -2.4% | ||
| 12-month return, skipping the last month | -26.4% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.5% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 110.27M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −4.7% |
|---|---|
| 1 month | −1.1% |
| 3 months | −3.3% |
| 6 months | −2.4% |
| 1 year | −27.2% |
| 3 years | +48.5% |
| 5 years | +7.4% |
Signals
| 50-day / 200-day average | 79.00 / 77.87 |
|---|---|
| Golden / death cross (60 days) | Golden, 27 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.52 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.